– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 – – MARIO-P, a study designed to expand ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today announced its third quarter 2021 financial results and provided a corporate update ...
Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the company's Operations and Full Year 2021 Financial Results. My name is Crystal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results